卡维地洛联合替米沙坦或吲达帕胺治疗顽固性高血压疗效的对比研究  

Effect of Carvedilol Combined with Telmisartan or Indapamide on Refractory Hypertension: A Comparative Study

作　　者：蔡文标[1] 冯建启[1] 刁军[1] 武维恒[1] 

机构地区：[1]徐州医学院第二附属医院心内科,江苏省徐州市221006

出　　处：《实用心脑肺血管病杂志》2014年第9期77-78,共2页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

摘　　要：目的对比卡维地洛联合替米沙坦或吲达帕胺治疗顽固性高血压的临床疗效。方法选取我院2009年1月—2012年11月收治的顽固性高血压患者90例,采用单双号方法分为A组和B组,每组45例。A组患者给予卡维地洛联合吲达帕胺治疗,B组患者给予卡维地洛联合替米沙坦治疗;两组患者均根据血压达标情况调整用药剂量。观察两组患者临床疗效和不良反应情况。结果 A组患者总有效率为91.11%,B组为93.33%,差异无统计学意义(P>0.05)。A组患者不良反应发生率为26.67%,高于B组的13.33%(P<0.05)。结论卡维地洛联合替米沙坦或吲达帕胺治疗顽固性高血压均具有良好的临床疗效,而卡维地洛联合替米沙坦治疗引起的不良反应少,安全性较高。Objective To compare the effect of carvedilol combined with telmisartan or indapamide on refractory hypertension. Methods From January 2009 to November 2012,90 patients with refractory hypertension were chosen in our hospital,and they were divided into groups A and B according to odd- even number method,45 cases in each. A group given carvedilol combined with indapamide,B group given carvedilol combined with telmisartan,both groups adjusted drugs doses based on blood pressure. Clinical effect and adverse reactions were observed. Results The total effective rate of A group was 91. 11%,that of B group was 93. 33%,the difference was not statistically different（P〉0. 05）. The incidence of adverse reactions of A group was 26. 67%,was higher than that of B group of 13. 33%（ P〈0. 05）. Conclusion Either carvedilol combined with telmisartan or indapamide has similar effect on refractory hypertension,while carvedilol combined with telmisartan has fewer adverse reactions,is more safe.

关 键 词：高血压 药物疗法 联合 卡维地洛 替米沙坦 吲达帕胺 

分 类 号：R544.1[医药卫生—心血管疾病]